NVIDIA BioNeMo 리뷰

Generate Biomedicines focuses on generative protein design, utilizing AI to create novel protein therapeutics by learning from protein sequences, structures, and biological function.

Similar to NVIDIA BioNeMo in its use of AI for biomolecular generation and prediction, Generate Biomedicines specializes in protein therapeutics and integrates a 'generate-build-measure-learn' loop for experimental feedback. BioNeMo offers a broader toolkit that also includes small molecule generation and a wider array of biomolecular models.

Evo 2 is a genomic foundation model capable of generalist prediction and design tasks across DNA, RNA, and proteins, trained with 40 billion parameters.

Evo 2 is directly comparable to NVIDIA BioNeMo in its foundational model approach for diverse biomolecules. While BioNeMo integrates specific models like OpenFold and ESMFold for protein structure prediction, Evo 2 is presented as a single genomic foundation model for prediction and design across multiple biological sequences.

Insilico Medicine is a pioneer in generative chemistry, leveraging AI to design novel small molecules and accelerate drug discovery, with a focus on advancing drugs into clinical phases.

Insilico Medicine's primary strength lies in generative AI for small molecule design, which is a key component of NVIDIA BioNeMo's broader offering that also includes protein generation and prediction. Insilico Medicine has a notable track record of moving AI-designed drugs into clinical trials.

Aurigene.AI is an AI-powered cloud platform designed to accelerate the entire Design-Make-Test-Analyze (DMTA) cycle for various molecule types, including small molecules, peptides, and biologics.

Aurigene.AI offers a comprehensive, end-to-end AI platform for drug discovery, similar to NVIDIA BioNeMo's broad framework. It supports a wider range of molecule types and integrates across the entire DMTA cycle, whereas BioNeMo emphasizes its suite of biomolecular prediction and generation models.